2008•Clinical MedicineRequires access
Short-course moxifloxacin therapy in the treatment of community-acquired pneumonia
Zhou Ya
Open publisher page 0 citations
Abstract
Objective To evaluate the efficacy,safety of short-course moxifloxacin therapy in the treatment of community-acquired pneumonia.Methods This analysis was based on the outcomes in 87 patients with mild to moderate community-acquired pneumonia.Patients were randomized to receive moxifloxacin therapy for 10 days(control group) or 5 days(short-course therapy group).Results ①The overall cure rates and efficacy rates were 68.2% and 90.9% in control group,65.1% and 88.4% in short-course therapy group,respectively.The bacterial clearance rates were 88.2% in control group and 87.9% in short-course therapy group,respectively.There was no significant difference between the two groups in the above results(P0.05).②The incidences of adverse drug reaction were 9.1% in control group and 7.0% in short-course therapy group,respectively.There was no significant difference between the two groups(P0.05).Conclusion The short-course moxifloxacin therapy in the treatment of community-acquired pneumonia was as effective and safe as the standard therapy.